Truist Securities Maintains Buy on PROCEPT BioRobotics, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Buy rating on PROCEPT BioRobotics (NASDAQ:PRCT) and raises the price target from $72 to $79.
July 16, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on PROCEPT BioRobotics and increased the price target from $72 to $79, indicating confidence in the company's future performance.
The reaffirmation of the Buy rating and the increase in the price target suggest that the analyst sees strong potential for growth in PROCEPT BioRobotics. This positive outlook is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100